Abstract
ABSTRACTMyasthenia gravis (MG) is a disorder of neuromuscular junction associated with presence of antibodies against nicotinic acetylcholine receptors (nAChRs). Here, we compared the clinical and serological profile of seropositive myasthenia gravis (SPMG) and seronegative myasthenia gravis (SNMG) patients. Anti-AChR antibody was measured using radio receptor immunoassay and correlated with clinical phenotype in 250 MG patients over 2004 and 2006. Out of 250 MG patients, 161 (64.4%%) were males (male:female == 1.8:1). SNMG patients formed 40%% (n == 101) of our MG patients which is much higher as compared to Caucasian and Oriental population (15%%–20%%). The median age of disease onset in SPMG was significantly higher than SNMG patients (43 years; range 8–74 vs. 35 years; range 4–72, p == .022). A bimodal peak of age of disease onset in both genders was observed (first peak in second–third decades and second one in fifth–sixth decades). Among the MG patients with late-onset of disease, male were significantly higher compared to Caucasian and Oriental MG population (p == .047). MG patients with thymoma were significantly older and consisted of higher percent of males. Bulbar symptoms and severe grade (IIB++ III++ IV) at disease onset were more frequent in SPMG than SNMG patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.